3 - Kairos Pharma, LTD. (0001962011) (Issuer)

4 - Kairos Pharma, LTD. (0001962011) (Issuer)

4 - Kairos Pharma, LTD. (0001962011) (Issuer)

4 - Kairos Pharma, LTD. (0001962011) (Issuer)

4 - Kairos Pharma, LTD. (0001962011) (Issuer)

4 - Kairos Pharma, LTD. (0001962011) (Issuer)

4 - Kairos Pharma, LTD. (0001962011) (Issuer)

3 - Kairos Pharma, LTD. (0001962011) (Issuer)

3 - Kairos Pharma, LTD. (0001962011) (Issuer)

3 - Kairos Pharma, LTD. (0001962011) (Issuer)

4 - Kairos Pharma, LTD. (0001962011) (Issuer)

4 - Kairos Pharma, LTD. (0001962011) (Issuer)

4 - Kairos Pharma, LTD. (0001962011) (Issuer)

8-K - Kairos Pharma, LTD. (0001962011) (Filer)

8-K - Kairos Pharma, LTD. (0001962011) (Filer)

424B3 - Kairos Pharma, LTD. (0001962011) (Filer)

SCHEDULE 13G/A - Kairos Pharma, LTD. (0001962011) (Subject)

10-Q - Kairos Pharma, LTD. (0001962011) (Filer)

10-K/A - Kairos Pharma, LTD. (0001962011) (Filer)

8-K - Kairos Pharma, LTD. (0001962011) (Filer)

8-K - Kairos Pharma, LTD. (0001962011) (Filer)

8-K - Kairos Pharma, LTD. (0001962011) (Filer)

DEFR14A - Kairos Pharma, LTD. (0001962011) (Filer)

Event to feature principal investigators from the trial Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces that it will host a premier KOL event on Thursday, Sept. 18th at 5 p.m. ET / 2 p.m. PT to discuss diverse perspectives on the Company's interim efficacy results from a Phase 2 trial of its lead candidate, ENV105, in treating advanced prostate cancer patients. Registration is required to participate in the webcast. Interested participants can sign-up to receive the webcast link here. "The safety results of the trial are an important catalyst as we prepare for the announcement of our interim efficacy

Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces participation and presentation of initial Phase 1 data of ENV105 in non-small cell lung cancer by Principal Investigator Dr. Karen Reckamp. Dr. Reckamp will present at the World Lung Cancer Conference which takes place September 6-9, 2025, at the Fira de Barcelona Gran Via in Barcelona, Spain. Dr. Reckamp's presentation, "Combination of Osimertinib and Carotuximab for Advanced, EFGR-Mutated Non-Small Cell Lung Cancer Patients," focuses on combination therapy of ENV105 with osimertinib for the treatment of non-small cell lung cancer. More information on the

Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces that John Yu, MD, CEO and Chairman, will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference. The conference is being held on September 8 – 10, 2025 at the Lotte New York Palace Hotel. Presentation Date:  September 5, 2025 Time:  Available on-demand starting at 7:00 AM Eastern Time Webcast Link: https://journey.ct.events/view/567df3a2-9eaf-4575-bb61-3cdabd42346f A webcast of the presentation can be accessed on the investor relations section of the Kairos Pharma website. A r

Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces participation and presentation at the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8–10, 2025, at the Lotte New York Palace Hotel in New York City. Kairos Pharma will participate in on-on-one meetings and present at the meeting which will be available virtually and hosted on the kairospharma.com website. John Yu, MD, CEO and Chairman, will be hosting one-on-one meetings during the meeting September 8-10. To register for one-on-one meetings with management at The Lotte New York Palace Hotel in New York City please registe

Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces positive safety results from its ongoing Phase 2 clinical trial of ENV-105 (carotuximab) in patients with metastatic castration-resistant prostate cancer (mCRPC). The interim safety analysis of the trial demonstrated that ENV-105, a first-in-class CD105 antagonist, was well tolerated when combined with standard of care hormone therapy, apalutamide, from the first ten enrolled patients. Thus far, there have been no dose-limiting toxicities or unexpected adverse events reported to date. In addition, the treatment-related side effects were manageable with stand

Kairos Pharma, Ltd. (NYSE:KAPA), a clinical stage biopharmaceutical company, announces its presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting highlighting data on its investigational small molecule GITR ligand agonist KROS101. ASCO is being held May 30-June 3, 2025 at McCormick Place in Chicago, Ill. In the presentation titled, "Effect of KROS 101, a small molecule GITR ligand agonist, on T effector cells, T reg cells and intratumoral CD8 T cell cytotoxicity," the study authors presented their findings that demonstrated KROS 101's capability to act as a potent glucocorticosteroid-induced tumor necrosis factor receptor (GITR) ligand agonist with dual mecha

Kairos Pharma, Ltd. (NYSE:KAPA), a clinical stage biopharmaceutical company, announces it will be presenting at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting to be held May 30-June 3, 2025 at McCormick Place, Chicago, Ill. The poster is titled, "Effect of KROS 101, a small molecule GITR ligand agonist, on T effector cells, T reg cells and intratumoral CD8 T cell cytotoxicity," and will be presented on June 2. John Yu, M.D., Kairos CEO commented, "We look forward to the opportunity to continue to share data regarding our platform assets at one of the most prestigious oncology meetings in the world. We believe that KROS 101 has the potential to help optimize cancer tr

Kairos Pharma, Ltd. (NYSE:KAPA), a clinical stage biopharmaceutical company, today provides a letter to stockholders from CEO John Yu, M.D.: To our valued stockholders, As we reflect on the Company's progress before and after our initial public offering and listing on the NYSE American stock exchange, I am excited about what the future holds. We currently have two ongoing clinical trials for our lead drug, ENV105, which is being tested in patients with prostate cancer in a Phase 2 trial and is being tested in a Phase 1 trial for patients with a type of lung cancer (called EGFR-dependent non-small cell lung cancer). As part of these trials, we are also identifying and confirming biomarker

Kairos Pharma, Ltd. (NYSE:KAPA) is a clinical stage company involved in treating EGFR-driven lung cancer patients with ENV105 in combination with osimertinib after they fail to respond to single-agent osimertinib in a Phase 1 trial. Based on recent breakthroughs in understanding non-small cell lung cancer mechanism of resistance to first line osimertinib treatment, the U.S. Department of Defense ("DoD") is providing $876,000 to advance a strategy to identify patients that are starting to develop resistance at an early stage. The grant was awarded to identify biomarkers for the Company's clinical study to address the major challenge in achieving a lasting cure for lung cancer patients. The g

Company expects safety data readout in 2025 as Randomized Arm continues enrollment at key medical centers Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company (the "Company'"), announces the completion of the safety lead-in of its Phase 2 clinical trial of ENV105 for the treatment of metastatic, castration-resistant prostate cancer. The trial, titled, "Phase II study of Apalutamide with Carotuximab (ENV105) in Metastatic, Castration Resistant Prostate Cancer," began with the safety lead-in, which combined apalutamide, a standard of care for prostate cancer, with the Company's compound ENV105. The second part of the study, which randomizes patients to receive either